G Saglio


Affiliation: University of Turin
Country: Italy


  1. request reprint
    Saglio G, Cilloni D, Rancati F, Boano L. Glivec and CML: a lucky date. J Biol Regul Homeost Agents. 2004;18:246-51 pubmed
  2. Saglio G, Hochhaus A, Goh Y, Masszi T, Pasquini R, Maloisel F, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116:3852-61 pubmed publisher
    ..The current results suggested that dasatinib 140 mg once daily had similar efficacy and improved tolerability relative to the 70-mg twice-daily regimen in patients with imatinib-resistant, blast phase CML. ..
  3. Petiti J, Rosso V, Lo Iacono M, Calabrese C, Signorino E, Gaidano V, et al. Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. Leuk Res. 2018;67:6-11 pubmed publisher
    ..The assay allows evaluating WT1 rs16754 polymorphism in diagnostic routine to improve prognostic information faster and without over-costing for diagnostic laboratories. ..
  4. Saglio G, Kim D, Issaragrisil S, Le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9 pubmed publisher
    ..Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive CML. (ClinicalTrials.gov number, NCT00471497.) ..
  5. Morotti A, Rocca S, Carrà G, Saglio G, Brancaccio M. Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. Blood Rev. 2017;31:139-150 pubmed publisher
    ..This review focuses on MPN mouse models specifically developed to assess the pathogenetic roles of gene mutations found in human patients, as well as murine MPN-like phenotypes identified in genetically modified mice. ..
  6. Carrà G, Crivellaro S, Taulli R, Guerrasio A, Saglio G, Morotti A. Mechanisms of p53 Functional De-Regulation: Role of the I?B-?/p53 Complex. Int J Mol Sci. 2016;17: pubmed
    ..Here, we review the mechanisms of p53 functional inactivation, with a particular emphasis on the interaction between p53 and I?B-?, the NFKBIA gene product. ..
  7. Saglio G, Le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon F, et al. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Ann Hematol. 2017;96:1303-1313 pubmed publisher
    ..Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations. ..